|Table of Contents|

Value of coagulation index D-Dimer combined with Khorana scoring model in predicting the risk of venous thrombosis in tumor patients after chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 09
Page:
1712-1715
Research Field:
Publishing date:

Info

Title:
Value of coagulation index D-Dimer combined with Khorana scoring model in predicting the risk of venous thrombosis in tumor patients after chemotherapy
Author(s):
CHEN Lixia; LI Bo; HAN Yongqing
Shangrao People's Hospital，Jiangxi Shangrao 334000，China.
Keywords:
malignant tumor; chemotherapy; venous thrombosis; Khorana; fibrinogen; D-Dimer
PACS:
R730.6
DOI:
10.3969/j.issn.1672-4992.2023.09.024
Abstract:
Objective：To investigate the value of coagulation index combined with Khorana score in predicting the risk of venous thrombosis in tumor patients receiving chemotherapy.Methods：A total of 100 patients with malignant tumors diagnosed and treated with chemotherapy were selected in a Grade Ⅲ Grade A hospital from January 2019 to September 2022.Sixty patients with VTE were selected as the test group，and forty patients without VTE were selected as the control group.VTE was diagnosed by color Doppler ultrasound or pulmonary angiography.General data and coagulation indexes(D-Dimer and fibrinogen) were compared between the two groups.The sensitivity and specificity of coagulation index combined with Khorana score in predicting the risk of venous thrombosis in tumor patients were evaluated by drawing ROC curve.Results：The D-Dimer and fibrinogen in the two groups were statistically different(P＜0.05).The D-Dimer and fibrinogen in the test group were significantly higher than those in the control group.The predictive value of D-Dimer for thrombosis was higher than that of fibrinogen.The optimal cutoff value of D-Dimer was 2.28 mg/L.The D-Dimer was included in the evaluation item of Khorana model，and 1~3 points were assigned.In the evaluation model with assigning 2 points，the specificity and sensitivity of thrombus prediction of the new evaluation model were significantly improved compared with that of Khorana model，with AUC of 0.901，Youden index of 0.658，sensitivity of 0.733，and specificity of 0.925.Conclusion：As a coagulation index，D-Dimer is of great significance in improving the thrombosis prediction of Khorana model for tumor patients receiving chemotherapy.

References:

［1］KHORANA AA.Venous thromboembolism prevention in cancer outpatients［J］.J Natl Compr Canc Netw，2013，11(11):1431-1438.
［2］CAPRINI JA.Risk assessment as a guide for the prevention of the many faces of venous thromboembolism［J］.Am J Surg，2010，199(1S):S3-10.
［3］HENRIK TOFT SRENSEN A，CLAUS SVRKE A，DORA K，et al.Superficial and deep venous thrombosis，pulmonaryembolism and subsequent risk of cancer［J］.European Journal of Cancer，2012，48(4):586-593.
［4］KUENEN BC，LEVI M，MEIJERS JC，et al.Potential role of platelets inendothelial damage observed during treatment with cisplatin，gemcitabine，and the angiogenesis inhibitor SU5416［J］.J Clin Oncol，2003，21(11):2192-2198.
［5］ENDE-VERHAAR YM，CANNEGIETER SC，VONK NOORDEGRAAF A，et al.Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism：a contemporary view of the pulished literature［J］.Eur Respir J，2017，49(2)：1601792.
［6］SUSAN R KAHN.The post-thrombotic syndrome［J］.Hematology Am Soc Hematol Educ Program，2016，2(1):413-418.
［7］KAHN SR，COMEROTA AJ，CUSHMAN M，et al.American heart association council on peripheral vascular disease，council on clinical cardiology，and council on cardiovascular and stroke nursing.The postthromboticsyndrome：evidence-based prevention，diagnosis，and treatment strategies：a scientific statement from the American heart association［J］.Circulation，2014，130(18):1636-1661.
［8］MANSFIELD AS，TAFUR AJ，KOURELIS TV，et al.Predictors of active cancer thromboembolic outcomes：validation of the Khorana score among patients with lung cancer［J］.Thromb Haemost，2016，14(9):1773-1778.
［9］BRYCE A KERLIN，ROSE AYOOB，WILLIAM E SMOYER.Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease［J］.Clin J Am Soc Nephrol，2012，7(3):513-520.
［10］周坤，周玉珍，郑遵荣，等.血栓四项在恶性肿瘤患者静脉血栓形成中的应用研究［J］.中国医师进修杂志，2019，42(11):994-999. ZHOU K，ZHOU YZ，ZHENG ZR，et al.Application of four items of thrombus in venous thrombosis of patients with malignant tumor［J］.Journal of Chinese Physician，2019，42(11):994-999.
［11］PATELL R，RYBICKI L，MCCRAE KR，et al.Predicting risk of venous thromboembolism inhospitalized cancer patients：utility of a risk assessment tool［J］.Am J Hematol，2017，92(6):501-507.
［12］KHORANA AA，MACKMAN N，FALANGA A，et al.Cancer-associated venous thromboembolism［J］.Nat Rev Dis Primers，2022，8(1):11.
［13］KHORANA AA，FRANCIS CW，CULAKOVA E，et al.Frequency，risk factors，and trends for venous thromboembolism among hospitalized cancer patients［J］.Cancer，2007，110(10):2339-2346.
［14］LUBETSKY A.Pulmonary embolism in cancer patients：A review［J］.Isr Med Assoc J，2022，24(3):179-182.
［15］KAHN SR.How I treat postthrombotic syndrome［J］.Blood，2009，114(21)：4624-4631.
［16］STACY A MANDRAS，HIRSCH S MEHTA，ANJALI VAIDYA.Pulmonary hypertension：A brief guide for clinicians［J］.Mayo Clin Proc，2020，95(9):1978-1988.
［17］MARCILLAC I，IBRAHIM A，HAYAT M.Thrombosis and cancer［J］.Bull Cancer，1993，80(10):845-851.
［18］DASHE J，PARISIEN RL，PINA M，et al.Is the Caprini score predictive of venothromboembolism events in orthopaedic fracture patients［J］.J Orthop Trauma，2019，33(6):269-275.
［19］CRONIN M，DENGLER N，KRAUSS ES，et al.Completion of the updated Caprini risk assessment model［J］.Cli Appl Thromb Hemost，2019，25(4):1076-1082.
［20］ABDULLAH PANDOR，MICHAEL TONKINS，STEVE GOODACRE.Risk assessment models for venous thromboembolism in hospitalised adult patients：a systematic review［J］.BMJ Open，2021，11(7):44-45.
［21］莫才连，张晖，王士勇，等.99 例晚期恶性肿瘤患者静脉血栓栓塞症的诊治情况分析［J］.现代肿瘤医学，2020，28(7):1186-1189. MO CL，ZHANG H，WANG SY，et al.Analysis of diagnosis and treatment of thromboembolismin 99 cases of patients with advanced malignant tumor［J］.Modern Oncology，2020，28(7)：1186-1189.

Memo

Memo:
江西省卫生健康委员会科技计划项目（编号：202120040）
Last Update: 2023-03-30